"Escape" Phenomenon of the Antihypertensive Therapy Efficacy (ESCAPE)
The Role of Ambulatory Blood Pressure Characteristics, Features of the Structural and Functional Vascular Wall State, the Presence and Severity of Obstructive Sleep Apnea Syndrome in Predicting the "Escape" Phenomenon of the Antihypertensive Therapy Efficacy.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation
- Oksana Mikhailova
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Arterial hypertension (AH) grade 1-3, stage I-II
- High compliance during the follow-up period (≥ 85%)
- Initially achieved target office BP levels while taking 2-3-component AHT
Exclusion Criteria:
- Secondary AH
- Resistant AH,
- AH III stage,
- PAP- therapy,
- type 2 diabetes mellitus,
- pregnancy
- history of low adherence to treatment
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
"Escape" Phenomenon of the Antihypertensive Therapy Efficacy
Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT.
|
Assessment of the 24-h blood pressure profile
Other Names:
Assessment of the arterial stiffness
Assessment of the arterial stiffness
Assessment of the sleep breath disturbances
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of BP increasing higher the target level when taking the same therapy
Time Frame: 1-6 months
|
Assessment of attenuation of efficacy of previously adequate antihypertensive therapy by using different BP measurement methods
|
1-6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease course: assessment of major CVE and death occurrence
Time Frame: 10 years
|
Assessment of the disease course depending on the characteristics of 3-6th months of observation
|
10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 115061870017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arterial Hypertension
-
NCT07612657Not yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
NCT07217522RecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder) | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
-
NCT07601295Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07457762RecruitingPulmonary Arterial Hypertension (PAH)
-
NCT07357974Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07177703Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07266519Not yet recruiting
-
NCT07487441Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)
-
NCT07207525Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT06845579RecruitingUncontrolled Arterial Hypertension
Clinical Trials on Ambulatory blood pressure measurement device
-
NCT04065620RecruitingArterial Hypertension | Frailty Syndrome | Heart Failure With Preserved Ejection Fraction | Comorbidities and Coexisting Conditions
-
NCT02347436CompletedHypertension | Prostatic Hyperplasia
-
NCT05395403CompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White Coat
-
NCT04307004Completed
-
NCT03709771TerminatedMelanoma | Renal Cell Carcinoma | Hypertension | Cancer
-
NCT05866445Completed
-
NCT02003469Completed